Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 25, 2018 (8 years ago)

Enalapril Maleate Tablets USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specification; out-of-specification results for the Enalapril DKT degradant

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Enalapril Maleate Tablets USP, 5 mg, 100 Tablets (10X10) blister cards, 12 cartons in a shipper, Rx, Packaged and Distributed by: American Health Packaging, Columbus, OH --- NDC 68084-390-01 Carton [68084-390-11 - Unit Dose]

Affected NDCs 68084-0390-01 68084-0390-11

Compare with the code on your package — it is the most precise check available.

Drug: Enalapril Category: Blood Pressure Medication

Recalling firm
American Health Packaging
NDC code
68084-390-01
Origin
OH, United States
FDA recall number
D-0915-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Enalapril recalls

See all
Class II · Moderate risk

Enalapril Maleate Tablets

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

Ongoing Impurity / degradation JB Chemicals and Pharmaceuticals Ltd NDC 64980-688-10 D-0520-2026

Other recalls by American Health Packaging

All 2018 recalls
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022